VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Dummer on Driver Mutations and Next Steps in Melanoma

Reinhard Dummer, MD
Published: Thursday, Sep 15, 2016



Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses driver mutations and next steps in the treatment of patients with melanoma.

There are several melanoma subtypes based on driver mutations in the MAP kinase pathway. Most of them are mutated for BRAF, and while there are several medications for those types of mutations, there is a huge medical need for specific treatments of NRAS mutations, says Dummer.

The NEMO trial, which randomly assigned patients to receive the combination of the MEK inhibitor binimetinib and dacarbazine or dacarbazine alone, demonstrated binimetinib's potential as an alternative treatment option for patients with NRAS-mutant melanoma. This is a good first step in this setting, says Dummer, but there is certainly room for improved outcomes in future studies.


Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses driver mutations and next steps in the treatment of patients with melanoma.

There are several melanoma subtypes based on driver mutations in the MAP kinase pathway. Most of them are mutated for BRAF, and while there are several medications for those types of mutations, there is a huge medical need for specific treatments of NRAS mutations, says Dummer.

The NEMO trial, which randomly assigned patients to receive the combination of the MEK inhibitor binimetinib and dacarbazine or dacarbazine alone, demonstrated binimetinib's potential as an alternative treatment option for patients with NRAS-mutant melanoma. This is a good first step in this setting, says Dummer, but there is certainly room for improved outcomes in future studies.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x